Omalizumab is primarily used in the treatment of moderate to severe persistent allergic asthma, particularly in patients whose symptoms are not well-controlled with inhaled corticosteroids. It works by targeting and neutralizing immunoglobulin E (IgE), a key player in allergic reactions, thereby reducing the frequency and severity of asthma attacks. Additionally, it is employed in the management of chronic idiopathic urticaria, a condition characterized by persistent hives without a known cause, providing relief from itching and skin lesions. Omalizumab is also being explored for its potential in treating other allergic conditions, such as food allergies and nasal polyps, offering hope for improved symptom control in these areas.